Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595254 · ClinicalTrials.gov registry record · NA
Digital Cognitive Behavior Therapy Program for Suicide Prevention
A NA study, sponsored by Montana State University.
- Completed
- Registry status
- NA
- Development phase
- 725
- Enrollment target
NCT03595254: Completed NA study, sponsored by Montana State University.
NCT03595254 is a NA study that has completed, run by Montana State University. The registered enrollment target is 725 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03595254, a NA study, has completed, sponsored by Montana State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 725 participants
- Enrollment target
Study Summary
This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among adults. The first 450 participants will participate in a randomized waitlist controlled trial. The remaining 550 participants will be provided the program immediately upon enrolling
Primary Outcome
Suicidal Thinking; Score range 7 (better) - 35(worse)
Interventions
- BEHAVIORAL Thrive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 725 participants |
| Start Date | 2018-11-16 |
| Est. Completion | 2020-04-08 |
| Phase | NA |
What the finished NCT03595254 record still lists
NCT03595254 is an interventional study that assigns participants to a tested intervention. The registered 725 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which Thrive is the first listed.
NCT03595254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03595254 about?
NCT03595254 is a clinical study titled "Digital Cognitive Behavior Therapy Program for Suicide Prevention". This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among adults. The first 450 participants will participate in a randomized waitlist controlled trial. The remaining 550 participant...
What is the current status of trial NCT03595254?
This trial is currently completed. It is a NA study. The enrollment target is 725 participants. The study started on 2018-11-16. Estimated completion is 2020-04-08.
What interventions are being tested in trial NCT03595254?
The interventions under investigation include: Thrive (BEHAVIORAL).
Who is sponsoring clinical trial NCT03595254?
This trial is sponsored by Montana State University, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03595254's enrollment target sits among peer trials
725 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI